Bicycle Therapeutics Past Earnings Performance
Past criteria checks 0/6
Bicycle Therapeutics's earnings have been declining at an average annual rate of -39%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 20.5% per year.
Key information
-39.0%
Earnings growth rate
56.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 20.5% |
| Return on equity | -48.7% |
| Net Margin | -669.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bicycle Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 27 | -181 | 60 | 0 |
| 30 Sep 23 | 25 | -162 | 59 | 0 |
| 30 Jun 23 | 23 | -140 | 52 | 0 |
| 31 Mar 23 | 15 | -124 | 48 | 0 |
| 31 Dec 22 | 14 | -113 | 50 | 0 |
| 30 Sep 22 | 15 | -101 | 50 | 0 |
| 30 Jun 22 | 16 | -87 | 48 | 0 |
| 31 Mar 22 | 14 | -78 | 42 | 0 |
| 31 Dec 21 | 12 | -67 | 32 | 0 |
| 30 Sep 21 | 12 | -66 | 35 | 0 |
| 30 Jun 21 | 11 | -62 | 34 | 0 |
| 31 Mar 21 | 11 | -56 | 32 | 0 |
| 31 Dec 20 | 10 | -51 | 29 | 0 |
| 30 Sep 20 | 12 | -38 | 22 | 0 |
| 30 Jun 20 | 9 | -37 | 19 | 0 |
| 31 Mar 20 | 9 | -35 | 16 | 0 |
| 31 Dec 19 | 14 | -31 | 15 | 0 |
| 30 Sep 19 | 10 | -33 | 13 | 0 |
| 30 Jun 19 | 11 | -31 | 11 | 0 |
| 31 Mar 19 | 11 | -26 | 10 | 0 |
| 31 Dec 18 | 7 | -22 | 8 | 0 |
| 30 Sep 18 | 7 | -21 | 9 | 0 |
| 31 Dec 17 | 2 | -16 | 6 | 0 |
Quality Earnings: 50BA is currently unprofitable.
Growing Profit Margin: 50BA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 50BA is unprofitable, and losses have increased over the past 5 years at a rate of 39% per year.
Accelerating Growth: Unable to compare 50BA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 50BA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: 50BA has a negative Return on Equity (-48.71%), as it is currently unprofitable.